{
    "clinical_study": {
        "@rank": "26788", 
        "arm_group": {
            "arm_group_label": "MSC2363318A", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 1, first-in-human, open-label, non-randomized, dose escalation, trial to\n      explore the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD)  and clinical\n      activity signals of MSC2363318A."
        }, 
        "brief_title": "First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumor", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age greater than or equal to (>=)18 years\n\n          -  Confirmed diagnosis of advanced solid tumor that may be controlled with p70S6K or Akt\n             inhibition based on the presence of already identified or potentially present\n             molecular alteration known or likely to affect the phosphoinositide 3-Kinase (PI3K)\n             pathway, such as: phosphate and tensin homolog (PTEN), phosphoinositide 3-Kinase\n             catalytic subunit alpha isoform (PI3KCA), protein kinase B (Akt), mammalian target of\n             rapamycin (mTOR), tumor sclerosis complex 1 (TSC1), tumor sclerosis complex 2 (TSC2),\n             epidermal growth factor receptor (ErbB1) (EGFR), human epidermal growth factor\n             receptor 2 (ErbB2), and liver kinase B1 (LKB1), and for which the subject had\n             previously been offered an approved therapy no standard curative or palliative\n             measures exist, or such available measures are not acceptable to the subject. In\n             particular:\n\n               1. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer subjects\n                  must have progressed on or have been intolerant to at least 2 lines of\n                  HER2-directed therapy, and\n\n               2. Epidermal growth factor receptor (EGFR)-mutation positive lung cancer subjects\n                  must have progressed on or have been intolerant to an EGFR inhibitor\n\n          -  Measurable disease using clinically appropriate criteria for the type of malignancy,\n             RECIST version 1.1 for solid tumors and Cheson 2007 for lymphoma\n\n          -  A tumor accessible for biopsies and consent to undergo tumor biopsies before and\n             during MSC2363318A treatment\n\n          -  Ability to read and understand the informed consent form and willingness and ability\n             to give informed consent and demonstrate comprehension of the trial before undergoing\n             any trial activities\n\n          -  Negative blood pregnancy test at the screening visit for women of childbearing\n             potential\n\n          -  Willingness to avoid pregnancy and breast feeding beginning two weeks before the\n             first MSC2363318A dose and ending three months after the last trial treatment. Male\n             subjects with female partners of childbearing potential and female subjects of\n             childbearing potential must use adequate contraception in the judgment of the\n             Investigator, such as a two barrier method or a one barrier method with spermicide or\n             intrauterine device\n\n        Exclusion Criteria:\n\n          -  Eastern Cooperative Oncology Group Performance Status >=2\n\n          -  Previous therapy with:\n\n               -  Chemotherapy, immunotherapy, hormonal therapy (except low dose corticosteroids),\n                  biologic therapy, or any other anticancer therapy within 28 days (or five\n                  elimination half-lives for noncytotoxics, whichever is shorter) of Day 1 of\n                  trial drug treatment (6 weeks for nitrosureas or mitomycin\n\n               -  Any investigational agent within 28 days of Day 1 of trial drug treatment\n\n               -  Extensive prior radiotherapy on more than 30 percent of bone marrow reserves, or\n                  prior bone marrow/stem cell transplantation within 5 years from enrollment\n\n          -  Ongoing toxicity (except alopecia) due to a prior therapy, unless returned to\n             baseline or Grade 1 or less\n\n          -  Major surgical intervention or participation in a therapeutic clinical trial within\n             28 days from Day 1 of the first dose of MSC2363318A\n\n          -  Bone marrow impairment, renal impairment, liver function abnormality and impaired\n             cardiac function as defined in the protocol\n\n          -  History of cerebral vascular accident or stroke within the previous 2 years\n\n          -  Uncontrolled hypertension\n\n          -  Known active central nervous system (CNS) metastases (unless stable by computed\n             tomography [CT] scan for at least 1 month without evidence of cerebral edema and no\n             requirements for corticosteroids or anticonvulsants)\n\n          -  History of difficulty swallowing, malabsorption or other chronic gastrointestinal\n             disease or conditions that may hamper compliance and/or absorption of the\n             investigational product\n\n          -  Known human immunodeficiency virus, viral hepatitis, or tuberculosis positivity\n\n          -  Legal incapacity or limited legal capacity\n\n          -  Any other condition which, in the opinion of the Investigator, might impair the\n             subject's tolerance of trial treatment, the safety of the individual subject or the\n             outcome of the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01971515", 
            "org_study_id": "EMR100018-001"
        }, 
        "intervention": {
            "arm_group_label": "MSC2363318A", 
            "description": "MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached.", 
            "intervention_name": "MSC2363318A", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "MSC2363318A", 
            "Maximum tolerated dose", 
            "Dose limiting toxicities", 
            "Recommended phase 2 dose"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "afortier@mdanderson.org", 
                    "last_name": "Adoneca Fortier, BA", 
                    "phone": "(713) 563-9458"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Apostolia Maria Tsimberidou, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "United States", 
                        "state": "Vermont"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies", 
        "overall_contact": {
            "last_name": "Please Contact U.S. Medical Information Located in Rockland, MA, United States", 
            "phone": "888-275-7376"
        }, 
        "overall_official": {
            "affiliation": "EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany", 
            "last_name": "Remigiusz Kaleta", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of dose limiting toxicities (DLTs)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Day 21 of Cycle 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01971515"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacodynamic marker level of ribosomal protein S6 (RPS6) phosphorylation in blood and tumor tissue", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2"
            }, 
            {
                "measure": "Change in glucose metabolism as assessed by  fluorodeoxyglucose positron emission tomography /computed tomography (FDG PET/CT) in  target lesions", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 1 of Cycle 2 and end of treatment (at tumor progression)"
            }, 
            {
                "measure": "Pharmacokinetics parameters: Cmax, Tmax, AUC (0-tau), AUC (0-t), AUC (0-infinity), T(1/2), CL/f, CLss/f, Vz/f, Vss/f, Racc (AUC), Racc (Cmax), CLR, Ae (0-tau)", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2"
            }, 
            {
                "measure": "Number of subjects with best overall response according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) or Cheson 2007", 
                "safety_issue": "No", 
                "time_frame": "Evaluation were performed on Day 1 of every alternate cycle until tumor progression"
            }, 
            {
                "description": "Percentage of subjects with clinical benefit is defined as subjects with complete response (CR) or partial response (PR) at week 12, based on tumor assessment as determined by RECIST version 1.1 or Cheson 2007.", 
                "measure": "Percentage of subjects with clinical benefit", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Number of subjects with Treatment-emergent adverse events (TEAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to Day 30 after the last dose of study treatment"
            }
        ], 
        "source": "EMD Serono", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}